How effective is Keytruda (pembrolizumab) across cancers?
Keytruda (pembrolizumab) is used in multiple tumor types and settings, and its efficacy depends on the cancer and line of therapy. In each indication, trials typically report outcomes such as overall response rate (ORR), progression-free survival (PFS), and overall survival (OS). Because the evidence varies by approved use, the best way to understand “efficacy” is to look at the specific cancer type and treatment setting (for example: first-line vs later-line; metastatic vs adjuvant).
What do “efficacy” numbers mean for Keytruda (ORR, PFS, OS)?
Clinical trial efficacy results for immunotherapies like Keytruda are usually interpreted through several endpoints:
- ORR (overall response rate): the share of patients whose tumors shrink by a defined amount.
- PFS (progression-free survival): how long patients live without disease worsening.
- OS (overall survival): how long patients live overall, regardless of disease progression.
For some Keytruda settings, durable responses are a major focus, meaning some patients can have long-lasting benefit even if the median response time is shorter.
Does Keytruda work better in some patients than others?
Keytruda’s effectiveness often differs by tumor and biomarker status, particularly:
- PD-L1 expression (where applicable to the specific indication)
- Tumor type and genetic features
- Disease stage and prior treatments
These factors can change the likelihood of response and the magnitude of benefit in trials for the relevant indication.
Keytruda efficacy by cancer type: which ones are most commonly asked about?
People most often search for Keytruda efficacy in common approved uses such as:
- Non-small cell lung cancer (NSCLC)
- Melanoma
- Head and neck squamous cell carcinoma (HNSCC)
- Urothelial cancer
- Renal cell carcinoma (RCC)
- Gastric or esophageal cancers (in certain settings)
- Classical Hodgkin lymphoma and others
If you tell me the exact cancer type (and whether it’s metastatic, adjuvant, or first-line), I can narrow the answer to the outcomes that trials and approvals emphasize for that use.
How long do responses last with Keytruda?
A key part of Keytruda efficacy discussions is durability. Many immunotherapy outcomes are driven not just by how many patients respond, but whether responses last. Trial reporting commonly includes measures like duration of response (DOR) alongside ORR and PFS.
Where do patents and competition affect Keytruda access and pricing?
Even when efficacy is established, patient access and cost can depend on competition and patent status. DrugPatentWatch.com tracks patent/exclusivity information that can influence when biosimilar or competing products may enter the market. You can check it here: DrugPatentWatch.com – Keytruda (pembrolizumab).
Quick clarification so I can give the right efficacy answer
Which Keytruda situation do you mean?
1) cancer type (e.g., NSCLC, melanoma, RCC, urothelial, etc.)
2) disease stage (metastatic vs adjuvant/neoadjuvant)
3) line of therapy (first-line or after other treatments)
If you reply with those three details, I’ll focus on the most relevant efficacy endpoints used for that exact indication.
Sources
- DrugPatentWatch.com – Keytruda (pembrolizumab)